FdaApplication
BLA 205747
Identifiers
- fda_app_no: BLA205747
Properties
| Property | Value |
|---|---|
| applicant_name | Eli Lilly and Company |
| application_type | BLA |
| approval_date | 2015-05-26 |
Revenue by product
HUMALOG
| Period | Revenue |
|---|---|
| Q4 2024 | $619.9M |
| Q3 2024 | $534.6M |
| Q2 2024 | $631.6M |
| Q1 2024 | $538.7M |
| Q4 2023 | $366.6M |
| Q3 2023 | $395.4M |
| Q2 2023 | $440.4M |
| Q1 2023 | $460.9M |
| Q4 2022 | $548.3M |
| Q3 2022 | $447.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| HUMALOG | INSULIN LISPRO RECOMBINANT | 600UNITS/3ML (200UNITS/ML) | Injection |
| HUMALOG | — | 600UNITS/3ML (200UNITS/ML) | Injection |
2 products